Is Brukinsa (Zanubrutinib) a Safer Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis.

Saved in:
Bibliographic Details
Title: Is Brukinsa (Zanubrutinib) a Safer Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis.
Authors: Hetta, Helal F.1 (AUTHOR) hhussen@ut.edu.sa, Salama, Ayman2 (AUTHOR), Aljuaid, Turki A.3 (AUTHOR), Mojmami, Yazan T.3,4 (AUTHOR), Alotibi, Riyadh S.3,5 (AUTHOR), Alqabaly, Ahmed M.1,3 (AUTHOR), Aldosari, Nawaf A.2,3 (AUTHOR), Alshahri, Sami A.3 (AUTHOR), Asiri, Walid I. A.3,4 (AUTHOR), Alamri, Raed S.3,5 (AUTHOR), Alanazi, Fayez A.3 (AUTHOR), Alenazi, Malek S. A.3 (AUTHOR), Albuhayri, Mohammed H.3 (AUTHOR), Ramadan, Yasmin N.4 (AUTHOR), Sayad, Reem5 (AUTHOR)
Source: Pharmaceuticals (14248247). Mar2026, Vol. 19 Issue 3, p467. 19p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:14248247
DOI:10.3390/ph19030467